A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus

This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to look at how the body uses or stores fats while taking each study drug.

Inclusion Criteria:

• Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) of less than 8.5%
• Otherwise fit and healthy
• Non smoker

Exclusion Criteria:

• Taking medication or supplements other than insulin to control diabetes.
• Suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia
• Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids